Continuous Hemofiltration During Extracorporeal Membrane Oxygenation in Adult Septic Shock: A Comparative Cohort Analysis

<b>Background and Objectives</b><i>:</i> Severe sepsis complicated by refractory shock is associated with high mortality. Adding continuous hemofiltration to venovenous extracorporeal membrane oxygenation (ECMO) may accelerate clearance of inflammatory mediators and improve haemodynamic stability, but evidence remains limited. We analysed 44 consecutive septic-shock patients treated with combined ECMO-hemofiltration (ECMO group) and compared them with 92 septic-shock patients managed without ECMO or renal replacement therapy (non-ECMO group). <b>Methods</b><i>:</i> This retrospective single-centre study reviewed adults admitted between January 2018 and March 2025. Demographic, haemodynamic, laboratory and outcome data were extracted from electronic records. Primary outcome was 28-day mortality; secondary outcomes included intensive-care-unit (ICU) length-of-stay, vasopressor-free days, and change in Sequential Organ Failure Assessment (SOFA) score at 72 h. <b>Results</b><i>:</i> Baseline age (49.2 ± 15.3 vs. 52.6 ± 16.1 years; <i>p</i> = 0.28) and APACHE II (27.8 ± 5.7 vs. 26.9 ± 6.0; <i>p</i> = 0.41) were comparable. At 24 h, mean arterial pressure rose from 52.3 ± 7.4 mmHg to 67.8 ± 9.1 mmHg in the ECMO group (mean change [∆] + 15.5 mmHg, <i>p</i> < 0.001). Controls exhibited a modest 4.9 mmHg rise that did not reach statistical significance (<i>p</i> = 0.07). Inflammatory markers decreased more sharply with ECMO (IL-6 ∆ -778 pg mL^-1 vs. -248 pg mL^-1, <i>p</i> < 0.001). SOFA fell by 3.6 ± 2.2 points with ECMO versus 1.6 ± 2.4 in controls (<i>p</i> = 0.01). Twenty-eight-day mortality did not differ (40.9% vs. 48.9%, <i>p</i> = 0.43), but ICU stay was longer with ECMO (median 12.5 vs. 9.3 days, <i>p</i> = 0.002). ΔIL-6 correlated with ΔSOFA (ρ = 0.46, <i>p</i> = 0.004). <b>Conclusions</b><i>:</i> ECMO-assisted hemofiltration improved early haemodynamics and organ-failure scores and accelerated cytokine clearance, although crude mortality remained unchanged. Larger prospective trials are warranted to clarify survival benefit and optimal patient selection.